NOVA screens 4.8M+ molecules across 7,000 protein targets for virtual drug discovery.
The simplest explanation
Like a drug discovery factory testing billions of potential medicines simultaneously using AI.
No jargon. No whitepapers. Just the facts.
Drug discovery takes 12+ years and costs $2.6 billion per approved drug. The biggest bottleneck is the computational experimentation phase — running molecular simulations to identify which of billions of candidate molecules are worth testing in a lab. Only major pharmaceutical companies can afford this.
NOVA screens 4.8M+ molecules across 7,000 protein targets for virtual drug discovery.
Nova (MetaNova Labs) screens 65 billion drug molecules to identify the most promising candidates, with 79% greater accuracy than previous methods. By distributing the compute across the Bittensor network, it makes pharmaceutical-grade molecular modeling accessible to any research team — not just the ones with supercomputers.
The best way to understand a new technology is to compare it to something familiar.
Nova (MetaNova Labs) screens 65 billion drug molecules to identify the most promising candidates, with 79% greater accuracy than previous methods. By distributing the compute across the Bittensor network, it makes pharmaceutical-grade molecular modeling accessible to any research team — not just the ones with supercomputers.
NOVAuses Bittensor's incentive layer to build something no single company could run alone.
Participants (called miners) on the NOVA subnet compete to produce the best outputs for drug discovery ai tasks. Anyone with the right hardware can join.
Validators continuously evaluate miner outputs against objective benchmarks. For NOVA, this includes Binding affinity prediction accuracy. There's no human committee — the protocol decides.
Miners are paid in the NOVA alpha token in proportion to how good their work is. This creates a continuous competitive pressure that drives quality up and cost down — structurally, not just as a promise.
Because every participant is aligned toward the same goal — producing the best drug discovery ai results — the network improves continuously without requiring a central team to manage it.
NOVA is Subnet 68 (SN68) on the Bittensor network — a decentralized AI protocol built on the TAO blockchain. NOVA screens 4.8M+ molecules across 7,000 protein targets for virtual drug discovery.
Drug discovery takes 12+ years and costs $2.6 billion per approved drug. The biggest bottleneck is the computational experimentation phase — running molecular simulations to identify which of billions of candidate molecules are worth testing in a lab. Only major pharmaceutical companies can afford this.
Nova (MetaNova Labs) screens 65 billion drug molecules to identify the most promising candidates, with 79% greater accuracy than previous methods. By distributing the compute across the Bittensor network, it makes pharmaceutical-grade molecular modeling accessible to any research team — not just the ones with supercomputers.
The NOVA subnet has its own alpha token on Bittensor's dTAO system. It trades in the Bittensor liquidity pool and its price reflects market demand for the subnet's services.
AlphaGap tracks NOVA using its aGap score — a composite of development activity, token flow, and social signals. This page is for informational purposes only and is not financial advice. Always do your own research before making any investment decisions.
AlphaGap tracks signals, whale flows, developer commits, and the aGap score for every Bittensor subnet — updated continuously. Find the alpha gap before everyone else.
Free preview · Pro from $29/mo · Premium from $49/mo